These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27183900)

  • 21. Phynx: an open source software solution supporting data management and web-based patient-level data review for drug safety studies in the general practice research database and other health care databases.
    Egbring M; Kullak-Ublick GA; Russmann S
    Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):38-44. PubMed ID: 19777533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review.
    Prada-Ramallal G; Takkouche B; Figueiras A
    BMC Med Res Methodol; 2019 Mar; 19(1):53. PubMed ID: 30871502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validating mortality in the German Pharmacoepidemiological Research Database (GePaRD) against a mortality registry.
    Ohlmeier C; Langner I; Garbe E; Riedel O
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):778-84. PubMed ID: 27061445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A probabilistic bias analysis for misclassified categorical exposures, with application to oral anti-hyperglycaemic drugs.
    Arfè A; Nicotra F; Ghirardi A; Simonetti M; Lapi F; Sturkenboom M; Corrao G
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1443-1450. PubMed ID: 27594547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Underuse of self-controlled designs in pharmacoepidemiology in electronic healthcare databases: a systematic review.
    Gault N; Castañeda-Sanabria J; Guillo S; Foulon S; Tubach F
    Pharmacoepidemiol Drug Saf; 2016 Apr; 25(4):372-7. PubMed ID: 26781227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacoepidemiology--an Irish perspective.
    Williams D; Feely J
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):641-5. PubMed ID: 11980254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Access to linked administrative healthcare utilization data for pharmacoepidemiology and pharmacoeconomics research in Canada: anti-viral drugs as an example.
    Rawson NS
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1072-9. PubMed ID: 19650154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women?
    Hurault-Delarue C; Chouquet C; Savy N; Lacroix I; Beau AB; Montastruc JL; Damase-Michel C
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):770-7. PubMed ID: 27018245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of pharmacy-based and diagnosis-based comorbidity measures from medical administrative data.
    Cortaredona S; Pambrun E; Verdoux H; Verger P
    Pharmacoepidemiol Drug Saf; 2017 Apr; 26(4):402-411. PubMed ID: 27910177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conducting Privacy-Preserving Multivariable Propensity Score Analysis When Patient Covariate Information Is Stored in Separate Locations.
    Bohn J; Eddings W; Schneeweiss S
    Am J Epidemiol; 2017 Mar; 185(6):501-510. PubMed ID: 28399565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Privacy issues in pharmacoepidemiology: the importance of weighing costs and benefits.
    Leufkens HG
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):659-62. PubMed ID: 11980257
    [No Abstract]   [Full Text] [Related]  

  • 32. Research Techniques Made Simple: Pharmacoepidemiology Research Methods in Dermatology.
    Noe MH; Gelfand JM
    J Invest Dermatol; 2018 Feb; 138(2):e13-e18. PubMed ID: 29389330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Nordic countries as a cohort for pharmacoepidemiological research.
    Furu K; Wettermark B; Andersen M; Martikainen JE; Almarsdottir AB; Sørensen HT
    Basic Clin Pharmacol Toxicol; 2010 Feb; 106(2):86-94. PubMed ID: 19961477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient.
    Roberts AW; Dusetzina SB; Farley JF
    J Comp Eff Res; 2015 Jan; 4(1):27-35. PubMed ID: 25565067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methods in pharmacoepidemiology.
    Sommet A; Pariente A
    Therapie; 2019 Apr; 74(2):187-197. PubMed ID: 30819408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linkage of mother-baby pairs in the German Pharmacoepidemiological Research Database.
    Garbe E; Suling M; Kloss S; Lindemann C; Schmid U
    Pharmacoepidemiol Drug Saf; 2011 Mar; 20(3):258-64. PubMed ID: 21351307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Major advances in international pharmacoepidemiology.
    Tilson HH
    Ann Epidemiol; 1990 Dec; 1(2):205-12. PubMed ID: 1669501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [From a Viewpoint of Clinical Settings: Pharmacoepidemiology as Reverse Translational Research (rTR)].
    Kawakami J
    Yakugaku Zasshi; 2017; 137(6):681-683. PubMed ID: 28566573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increasing use of prescription drugs in the United Kingdom.
    Zhang F; Mamtani R; Scott FI; Goldberg DS; Haynes K; Lewis JD
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):628-36. PubMed ID: 26710965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacoepidemiological research using French reimbursement databases: yes we can!
    Martin-Latry K; Bégaud B
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):256-65. PubMed ID: 20128015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.